Stockscreener 앱 받기
3.38
6.37%
-0.23
시간 외 거래:
3.38
Maxcyte Inc 주식(MXCT)의 최신 뉴스
Electroporation Enables Efficient Antibody Discovery By Mammalian Display - BioProcess Online
This MaxCyte Insider Increased Their Holding In The Last Year - Yahoo Finance
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
MaxCyte stock touches 52-week low at $3.23 amid market challenges - Investing.com
Will MaxCyte's Q2 Results Surpass Market Expectations? - RTTNews
CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc - GuruFocus.com
MaxCyte Celebrates 25 Years - Baystreet.ca
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - The Manila Times
MaxCyte Marks 25 Years of Innovation with Groundbreaking Cell Therapy Breakthrough | MXCT Stock News - StockTitan
MaxCyte stock touches 52-week low at $3.27 amid market shifts - Investing.com Canada
MaxCyte stock touches 52-week low at $3.27 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
FY2024 Earnings Estimate for MaxCyte Issued By William Blair - MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Call Transcript - MSN
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Investors ignore increasing losses at MaxCyte (LON:MXCT) as stock jumps 10% this past week - Simply Wall St
MaxCyte Files Quarterly Report, Highlights Financial Progress - TipRanks
MaxCyte’s Revenue Grows and Strategic Moves Unveiled - TipRanks
MaxCyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Constellation Energy Corp (CEG-Q) QuotePress Release - The Globe and Mail
MaxCyte Director Sells Shares Amid Active Trading - TipRanks
MaxCyte Expands Stock Capital with New Issuance - TipRanks
MaxCyte (LON:MXCT) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
MaxCyte to Participate in Two Upcoming Investor Conferences - StockTitan
MaxCyte to Join Key Investor Conferences in November - TipRanks
MaxCyte’s Insider Stock Activity in Focus - TipRanks
MaxCyte director Johnston sells $11,166 in stock - Investing.com
Overcome the limitations of conventional transfection with MaxCyte Electroporation - LabRoots
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - MarketBeat
Grant of Options and Restricted Stock Units - ShareCast
MaxCyte Awards Stock Options to Boost Growth - TipRanks
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
MaxCyte Appoints Cynthia Collins to its Board of Directors - ForexTV.com
MaxCyte Strengthens Board with Cynthia Collins Appointment - TipRanks
MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer - Head Topics
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - ForexTV.com
MaxCyte to Unveil Q3 2024 Financial Results - TipRanks
People on the Move: Ali Soleymannezhad, Chief Commercial Officer, MaxCyte - BioBuzz
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - citybiz
MaxCyte appoints new chief commercial officer - ShareCast
MaxCyte appoints Soleymannezhad as CCO - TipRanks
MaxCyte Names New CCO for Market Expansion - TipRanks
MaxCyte upgraded to Buy from Hold at Deutsche Bank - TipRanks
Marshall Wace LLP Acquires New Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha
Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock - MarketBeat
MaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in Stock - Defense World
0.03%
0.14%
자본화:
|
볼륨(24시간):